Evidence map›Paper›PMID 34739585›Full record

ArticleJournal of cancer research and clinical oncology2022

Role of FoxP3-positive regulatory T-cells in regressive and progressive cervical dysplasia.

Aurelia Vattai, Nadine Kremer, Sarah Meister, Susanne Beyer, Lucia Keilmann, Anna Hester, Mina Temelkov, Helene Heidegger, Elisa Schmoeckel, Mirjana Kessler and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Aurelia VattaiDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany. Aurelia.Vattai@med.uni-muenchen.de.
Nadine KremerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Sarah MeisterDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Susanne BeyerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Lucia KeilmannDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Anna HesterDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Mina TemelkovDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Helene HeideggerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Elisa SchmoeckelFaculty of Medicine, Institute of Pathology, LMU Munich, 80337, Munich, Germany.
Mirjana KesslerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Sven MahnerDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Udo JeschkeDepartment of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Linda Hertlein *Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
Thomas Kolben *Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 80337, Munich, Germany.
LMU Klinikum · DELudwig-Maximilians-Universität München · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeForkhead Box Protein 3 (FoxP3) is known as a key mediator in the immunosuppressive function of regulatory T-cells (Tregs). The aim of our study was to investigate whether FoxP3-positive Tregs have the potential to act as an independent predictor in progression as well as in regression of cervical intraepithelial neoplasia, especially in patients with intermediate cervical intraepithelial neoplasia (CIN II).

methodsNuclear FoxP3 expression was immunohistochemically analysed in 169 patient samples (CIN I, CIN II with regressive course, CIN II with progressive course, CIN III). The median numbers were calculated for each slide and correlated with the histological CIN grade. Statistical analysis was performed by SPSS 26 (Mann-Whitney U test, Spearman's rank correlation).

resultsAn increased FoxP3 expression in CIN II with progression could be detected in comparison to CIN II with regression (p = 0.003). Total FoxP3 expression (epithelium and dysplasia-connected stroma) was higher in more advanced CIN grades (p < 0.001 for CIN I vs. CIN II; p = 0.227 for CIN II vs. CIN III). A positive correlation could be detected between FoxP3-positive cells in epithelium and total FoxP3 expression (Spearman's Rho: 0,565; p < 0.01).

conclusionExpression of FoxP3 could be a helpful predictive factor to assess the risks of CIN II progression. As a prognosticator for regression and progression in cervical intraepithelial lesions it might thereby help in the decision process regarding surgical treatment vs. watchful waiting strategy to prevent conisation-associated risks for patients in child-bearing age. In addition, the findings support the potential of Tregs as a target for immune therapy in cervical cancer patients.

Indexed as

AdolescentAdultBiomarkers, TumorDisease ProgressionFemaleForkhead Transcription FactorsGermanyHumansImmunohistochemistryMiddle AgedNeoplasm Regression, SpontaneousPapillomavirus InfectionsPrognosisT-Lymphocytes, RegulatoryUterine Cervical DysplasiaUterine Cervical NeoplasmsBiomarkers, TumorForkhead Transcription FactorsFOXP3 protein, humanCervical intraepithelial neoplasiaConisationFoxP3HPVRegulatory T-cells

Identifiers

PMID34739585
PMCPMC11800877
OpenAlexW3210788187

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.